Cargando…
NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the clinical trials that led to the approval of these two drugs, most of the enrolled patients were affected by soft tissue sarc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695027/ https://www.ncbi.nlm.nih.gov/pubmed/36579526 http://dx.doi.org/10.3390/jpm12111819 |
_version_ | 1784837954020048896 |
---|---|
author | Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Rosenfeld, Roberto Guerriero, Simona Carlucci, Manuela Capotondi, Barbara Torino, Francesco Roselli, Mario |
author_facet | Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Rosenfeld, Roberto Guerriero, Simona Carlucci, Manuela Capotondi, Barbara Torino, Francesco Roselli, Mario |
author_sort | Iannantuono, Giovanni Maria |
collection | PubMed |
description | The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the clinical trials that led to the approval of these two drugs, most of the enrolled patients were affected by soft tissue sarcomas, lung, and salivary gland cancer. However, as next-generation sequencing assays are increasingly available in the clinical setting, health care professionals may be able to detect NTRK gene fusions in patients affected by tumor types under or not represented in the clinical trials. To this aim, we systematically reviewed MEDLINE from its inception to 31 August 2022 for case reports and case series on patients with NTRK gene fusion-positive tumors treated with TRK inhibitors. A virtual cohort of 43 patients was created, excluding those enrolled in the above-mentioned clinical trials. Although our results align with those existing in the literature, various cases of central nervous system tumors were registered in our cohort, confirming the benefit of these agents in this subgroup of patients. Large, multi-institutional registries are needed to provide more information about the efficacy of TRK inhibitors in cancer patients affected by tumor types under or not represented in the clinical trials. |
format | Online Article Text |
id | pubmed-9695027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96950272022-11-26 NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Rosenfeld, Roberto Guerriero, Simona Carlucci, Manuela Capotondi, Barbara Torino, Francesco Roselli, Mario J Pers Med Review The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the clinical trials that led to the approval of these two drugs, most of the enrolled patients were affected by soft tissue sarcomas, lung, and salivary gland cancer. However, as next-generation sequencing assays are increasingly available in the clinical setting, health care professionals may be able to detect NTRK gene fusions in patients affected by tumor types under or not represented in the clinical trials. To this aim, we systematically reviewed MEDLINE from its inception to 31 August 2022 for case reports and case series on patients with NTRK gene fusion-positive tumors treated with TRK inhibitors. A virtual cohort of 43 patients was created, excluding those enrolled in the above-mentioned clinical trials. Although our results align with those existing in the literature, various cases of central nervous system tumors were registered in our cohort, confirming the benefit of these agents in this subgroup of patients. Large, multi-institutional registries are needed to provide more information about the efficacy of TRK inhibitors in cancer patients affected by tumor types under or not represented in the clinical trials. MDPI 2022-11-02 /pmc/articles/PMC9695027/ /pubmed/36579526 http://dx.doi.org/10.3390/jpm12111819 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Rosenfeld, Roberto Guerriero, Simona Carlucci, Manuela Capotondi, Barbara Torino, Francesco Roselli, Mario NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series |
title | NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series |
title_full | NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series |
title_fullStr | NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series |
title_full_unstemmed | NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series |
title_short | NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series |
title_sort | ntrk gene fusions in solid tumors and trk inhibitors: a systematic review of case reports and case series |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695027/ https://www.ncbi.nlm.nih.gov/pubmed/36579526 http://dx.doi.org/10.3390/jpm12111819 |
work_keys_str_mv | AT iannantuonogiovannimaria ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries AT riondinosilvia ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries AT sgangastefano ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries AT rosenfeldroberto ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries AT guerrierosimona ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries AT carluccimanuela ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries AT capotondibarbara ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries AT torinofrancesco ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries AT rosellimario ntrkgenefusionsinsolidtumorsandtrkinhibitorsasystematicreviewofcasereportsandcaseseries |